Biopharma | January 11, 2026
Prokaryotics and Basilea team up to tackle deadly fungal infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The partnership aims to develop a first-in-class broad-spectrum antifungal to combat life-threatening invasive infections
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
The FDA designation follows visual-function results from the Phase 2 ACUITY trial
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
The MAGiC catheter is designed for robotically-navigated cardiac ablation procedures
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
Subscribe To Our Newsletter & Stay Updated
